Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Atai Beckley NV ATAI

Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.

Current News (NDAQ:ATAI)

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

GlobeNewswire 23 hours ago

atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies

GlobeNewswire 5 days ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

GlobeNewswire October 20, 2025

atai Life Sciences Announces Pricing of Public Offering of Common Shares

GlobeNewswire October 16, 2025

atai Life Sciences Announces Proposed Public Offering of Common Shares

GlobeNewswire October 16, 2025

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

GlobeNewswire October 16, 2025

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

GlobeNewswire September 23, 2025

atai Life Sciences Awarded Grant from the National Institutes of Health

GlobeNewswire September 18, 2025

atai Life Sciences to Participate in September Investor Conferences

GlobeNewswire August 28, 2025

Opinion & Analysis (NDAQ:ATAI)

No current opinion is available.

Bullboard Posts (NDAQ:ATAI)

Top 5 Shroom Stocks

https://thedalesreport.com/psychedelics/tdrs-top-5-psychedelic-developments-for-the-week-of-may-1/
StockJunkie4994 - May 8, 2023

Kevin Harrington Discusses FSD Pharma

<< View Post To Watch Video >> I believe this new product will aid society in reducing the number of alcohol-related...
Karylle - April 13, 2023

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent

   
Karylle - July 15, 2022

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

<< View Post To Watch Video >> FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets...
Karylle - June 3, 2022

FSD Pharma Files Investigational New Drug Application “IND”

 
Karylle - June 2, 2022

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

 
Karylle - May 11, 2022